Cannabinol (CBN): A Comprehensive Exploration of Its Scientific and Therapeutic Dimensions

1. Introduction to Cannabinoids

Cannabinoids are a diverse class of chemical compounds that interact with cannabinoid receptors in the human body, influencing a wide range of physiological processes. They originate primarily from the cannabis plant (Cannabis sativa and Cannabis indica) and are classified into three main categories: phytocannabinoids (plant-derived), endocannabinoids (produced within the body), and synthetic cannabinoids (manufactured artificially) 1.

The most widely studied cannabinoids are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), known for their psychoactive and therapeutic properties, respectively. However, there is growing interest in minor cannabinoids like cannabinol (CBN), cannabigerol (CBG), and cannabichromene (CBC) 2. These compounds are increasingly significant due to their unique pharmacological profiles and potential therapeutic applications.

Cannabinol (CBN) is particularly intriguing as it is not directly synthesized by the cannabis plant but is a degradation product of THC. Over time, THC oxidizes to form CBN, especially when exposed to heat, light, or air 3. This natural process means that CBN is commonly found in aged cannabis. The shift toward researching non-psychoactive cannabinoids has heightened interest in CBN, given its potential therapeutic benefits without the strong psychoactive effects associated with THC.

2. Chemical Structure and Properties of Cannabinol (CBN)

CBN has the molecular formula C₂₁H₂₆O₂ and a molecular weight of approximately 310.44 g/mol 4. Structurally, CBN is a bicyclic compound, sharing the core cannabinoid skeleton but differing in saturation and oxidation levels compared to THC and CBD.

The formation of CBN from THC involves the oxidation of THC’s pentyl side chain and aromatic ring system 5. Specifically, THC loses hydrogen atoms and forms additional double bonds, resulting in a molecule with altered electronic distribution and three-dimensional shape. This structural transformation affects CBN’s interaction with cannabinoid receptors.

CBN differs from THC and CBD in its degree of aromaticity and the absence of a double bond in the cyclohexene ring present in THC 6. These structural features contribute to CBN’s lower affinity for cannabinoid receptors, particularly the CB1 receptor, leading to significantly reduced psychoactivity.

Chemically, CBN is more stable than THC and less prone to further degradation 7. Environmental factors like heat, light, and air exposure accelerate the conversion of THC into CBN, explaining its prevalence in aged or improperly stored cannabis products.

3. Mechanism of Action

CBN interacts with the endocannabinoid system (ECS), a complex cell-signaling network crucial for maintaining physiological homeostasis 8. The ECS comprises cannabinoid receptors (CB1 and CB2), endogenous ligands (endocannabinoids), and enzymes responsible for ligand synthesis and degradation.

Partial Agonism at CB1 and CB2 Receptors

CBN acts as a partial agonist at both CB1 and CB2 receptors but with lower affinity and efficacy than THC 9. Its weak binding to CB1 receptors in the central nervous system correlates with its minimal psychoactive effects.

Interactions with Other Receptor Systems

  • TRPV2 Receptors: CBN activates Transient Receptor Potential Vanilloid 2 channels involved in nociception and inflammation 10.
  • PPAR-γ Receptors: CBN may modulate gene expression related to lipid metabolism and inflammation through Peroxisome Proliferator-Activated Receptor Gamma activation 11.
  • GABAergic Neurotransmission: CBN might influence gamma-aminobutyric acid (GABA) receptors, affecting neuronal excitability and potentially exhibiting sedative properties 12.

The Entourage Effect

The “entourage effect” suggests that cannabinoids and other cannabis compounds, like terpenes, may work synergistically to enhance therapeutic effects 13. CBN may contribute to this effect by interacting with other cannabinoids, potentially enhancing therapeutic outcomes or mitigating side effects.

4. Pharmacokinetics of Cannabinol (CBN)

Absorption

CBN can be administered via oral ingestion, sublingual absorption, inhalation, or topical application, with bioavailability varying accordingly:

  • Oral Administration: Low bioavailability (5-20%) due to first-pass metabolism in the liver 14.
  • Sublingual Administration: Increased bioavailability by bypassing the gastrointestinal tract and liver.
  • Inhalation: Rapid absorption through the lungs, with bioavailability of 10-35% 15.

Distribution

CBN is lipophilic, distributing rapidly into tissues with high lipid content, including the brain and adipose tissue 16. It crosses the blood-brain barrier less efficiently than THC.

Metabolism

Metabolized primarily by cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver, CBN is converted into hydroxylated metabolites like 11-hydroxy-CBN and 8-hydroxy-CBN 17. Factors such as age, liver function, and co-administration of other substances can influence metabolism.

Excretion

CBN and its metabolites are excreted via feces and urine. The elimination half-life is estimated to be 24-48 hours 18. Detection in the body can last from days to weeks, depending on usage patterns and individual metabolic factors 19.

5. Psychoactive Effects and Cognitive Implications

Psychoactivity

CBN is considered minimally psychoactive. Its affinity for CB1 receptors is about ten times lower than THC’s, resulting in negligible psychoactive effects at typical doses 20.

Cognitive Effects

Limited studies suggest that CBN may have sedative properties, potentially influencing sleep patterns 21. However, its impact on cognition, memory, attention, or focus appears minimal, especially at low to moderate doses.

Sedative Properties

Anecdotal reports and some preclinical studies propose that CBN acts as a sedative or sleep aid. A study from the 1970s indicated that CBN might enhance THC’s sedative effects 22. However, recent research is sparse, and definitive evidence supporting CBN as a sedative is limited 23.

Chronic Use and High Doses

Data on the effects of chronic CBN use or high-dose exposure are scarce. Given its low psychoactivity, significant cognitive impairment is unlikely, but further research is necessary to understand its long-term effects fully.

6. Therapeutic Applications of Cannabinol (CBN)

Analgesic and Anti-Inflammatory Effects

CBN has demonstrated potential as an analgesic in animal models, possibly modulating pain perception through TRPV2 channels and ECS modulation 24. Its anti-inflammatory properties could contribute to pain relief in inflammatory conditions.

Neuroprotective Effects

CBN has shown neuroprotective effects in preclinical studies. A 2005 study found that CBN delayed amyotrophic lateral sclerosis (ALS) onset in mice, suggesting potential benefits in neurodegenerative diseases 25. CBN may protect neurons by reducing oxidative stress and inflammation.

Glaucoma Management

CBN has been investigated for its ability to reduce intraocular pressure, a key factor in glaucoma. While less potent than THC, CBN may contribute to ocular health when combined with other cannabinoids 26.

Antibacterial Properties

CBN exhibits antibacterial activity, particularly against antibiotic-resistant strains like methicillin-resistant Staphylococcus aureus (MRSA) 27. This suggests potential as an antibacterial agent in combating resistant bacteria.

Appetite Stimulation

Rodent studies indicate that CBN may stimulate appetite, which could have therapeutic implications for conditions involving appetite loss, such as cancer cachexia 28.

Sleep Aid

Although evidence is limited, CBN’s potential sedative effects have led to its use in sleep disorder management and inclusion in nighttime cannabis formulations.

Ongoing Research and Clinical Trials

Current research explores CBN’s potential anti-tumor effects, role in modulating appetite and gastrointestinal health, and impact on autoimmune disorders and inflammatory diseases.

7. Side Effects and Safety Profile

Known Side Effects

CBN appears to have a favorable safety profile, with mild side effects reported:

  • Dry Mouth
  • Dizziness
  • Drowsiness

Serious adverse effects are rare and not well-documented 29.

Comparison with THC and CBD

Compared to THC, CBN has significantly lower psychoactivity and fewer side effects related to cognitive impairment. Its safety profile is similar to CBD’s, which is generally well-tolerated.

Dependence and Abuse Potential

Currently, there is no evidence suggesting that CBN leads to dependence or abuse. It lacks the euphoric effects associated with THC, reducing misuse likelihood 30.

Drug Interactions

CBN may inhibit cytochrome P450 enzymes CYP2C9 and CYP3A4, affecting the metabolism of other drugs and leading to interactions 31. Caution is advised when using CBN with medications extensively metabolized by these enzymes.

8. Legal and Regulatory Status

United States

CBN’s legal status in the U.S. is ambiguous. It is not explicitly scheduled under the Controlled Substances Act, but its derivation from THC raises regulatory concerns 32. Hemp-derived cannabinoids containing less than 0.3% THC are legal under the 2018 Farm Bill, but CBN’s classification remains unclear.

European Union

In the EU, CBN is not specifically scheduled, but regulations vary by country. The Novel Food Regulation may require authorization for CBN-containing products 33.

Canada

Under the Cannabis Act, CBN products are legal for medical and recreational use, provided they meet regulatory requirements 34.

Regulatory Challenges

  • Product Standardization: Lack of consistent quality and potency across products.
  • Safety Testing: Insufficient data on long-term effects necessitates rigorous testing.
  • Regulatory Guidance: Absence of clear frameworks specifically addressing CBN leads to market uncertainty.

9. Future Research Directions and Emerging Applications

Cancer Treatment

Preliminary studies suggest CBN may inhibit tumor cell growth, indicating potential in cancer therapy 35. Research aims to elucidate mechanisms and efficacy.

Autoimmune and Inflammatory Diseases

CBN’s anti-inflammatory effects may benefit autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease. Its immune system interactions are under study in various disease models 36.

Combination Therapies

Using CBN with other cannabinoids or pharmaceuticals may enhance therapeutic outcomes through synergistic effects, improving efficacy while minimizing side effects.

Wellness Industry Applications

CBN is gaining popularity in wellness products targeting relaxation, sleep improvement, and pain relief. Scientific validation is essential as consumer interest grows.

Advances in Cannabis Research

Enhanced understanding of minor cannabinoids like CBN through advanced research methodologies could lead to novel therapeutics and mainstream medical applications.

10. Conclusion

Cannabinol (CBN) stands out among minor cannabinoids due to its unique origin as a THC degradation product and its minimal psychoactive effects. Its potential therapeutic applications, including analgesic, neuroprotective, antibacterial, and appetite-stimulating effects, position CBN as a compound of significant interest.

While preclinical studies are promising, clinical evidence remains limited. The favorable safety profile and low risk of dependence make CBN an attractive candidate for further research. Regulatory ambiguity and lack of standardized products present challenges, but ongoing research and growing interest may pave the way for CBN’s inclusion in therapeutic regimens and wellness products.

Robust clinical trials are essential to establish CBN’s efficacy and safety conclusively. As cannabinoid research evolves, CBN holds promise in reshaping the future of cannabis-based therapeutics and wellness offerings.

References

Footnotes

  1. Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), 833. ↩
  2. Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241–254. ↩
  3. Morales, P., Reggio, P. H., & Jagerovic, N. (2017). An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Frontiers in Pharmacology, 8, 422. ↩
  4. World Health Organization. (2018). Cannabinol (CBN) Pre-Review Report. Retrieved from who.int ↩
  5. ElSohly, M. A., & Gul, W. (2014). Constituents of cannabis sativa. In Handbook of Cannabis (pp. 3–22). Oxford University Press. ↩
  6. Pertwee, R. G. (2015). Pharmacological actions of cannabinoids. In Handbook of Cannabis (pp. 115–143). Oxford University Press. ↩
  7. Calvi, L., et al. (2018). Photochemical degradation of cannabinoids. Natural Product Communications, 13(8), 1085–1090. ↩
  8. Lu, H. C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516–525. ↩
  9. Makriyannis, A., & Tian, X. (2014). Structure-activity relationships of the cannabinoid receptors. Current Pharmaceutical Design, 20(13), 2073–2084. ↩
  10. De Petrocellis, L., et al. (2008). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494. ↩
  11. Irving, A. J., et al. (2017). Cannabinoid receptor-related orphan G protein-coupled receptors. Advances in Pharmacology, 80, 223–247. ↩
  12. Barbara, G., et al. (2009). Neuroimmune interactions and enteric nervous system in the regulation of intestinal function. Neurogastroenterology & Motility, 21(6), 564–570. ↩
  13. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364. ↩
  14. Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemical Biodiversity, 4(8), 1770–1804. ↩
  15. McGilveray, I. J. (2005). Pharmacokinetics of cannabinoids. Pain Research & Management, 10(Suppl A), 15A–22A. ↩
  16. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids. British Journal of Pharmacology, 153(2), 199–215. ↩
  17. Jiang, R., et al. (2013). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences, 92(17-18), 740–745. ↩
  18. Ujváry, I., & Hanuš, L. (2016). Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis and Cannabinoid Research, 1(1), 90–101. ↩
  19. Hädener, M., et al. (2019). Long-term detection of synthetic cannabinoids in hair samples. Forensic Science International, 300, 58–64. ↩
  20. Fairbairn, J. W., & Pickens, J. T. (1981). Activity of cannabis in relation to its delta’-trans-tetrahydrocannabinol content. British Journal of Pharmacology, 72(3), 401–409. ↩
  21. Karniol, I. G., & Carlini, E. A. (1973). Pharmacological interaction between cannabidiol and delta9-tetrahydrocannabinol. Psychopharmacologia, 33(1), 53–70. ↩
  22. Musty, R. E., & Splinter, R. G. (1976). Cannabinoid-induced behavioral suppression in rats. Pharmacology Biochemistry and Behavior, 5(6), 671–677. ↩
  23. Gates, P. J., et al. (2017). The effects of cannabinoid administration on sleep: A systematic review of human studies. Sleep Medicine Reviews, 41, 72–81. ↩
  24. Zurier, R. B., & Burstein, S. H. (2016). Cannabinoids, inflammation, and fibrosis. The FASEB Journal, 30(11), 3682–3689. ↩
  25. Weydt, P., et al. (2005). Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 6(3), 182–184. ↩
  26. Colasanti, B. K., et al. (1984). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Experimental Eye Research, 39(3), 251–259. ↩
  27. Appendino, G., et al. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. Journal of Natural Products, 71(8), 1427–1430. ↩
  28. Farrimond, J. A., et al. (2012). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology, 223(1), 117–129. ↩
  29. WHO Expert Committee on Drug Dependence. (2018). Cannabinol Critical Review Report. Retrieved from who.int ↩
  30. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2015). Exploring novel psychoactive substances in Europe. Retrieved from emcdda.europa.eu ↩
  31. Arnold, J. C., et al. (2019). The potential clinical implications of cannabidiol interactions with cytochrome P450 complex enzymes. Epilepsia, 60(11), 2222–2228. ↩
  32. U.S. Drug Enforcement Administration. (2020). Controlled Substances Act. Retrieved from dea.gov ↩
  33. European Food Safety Authority. (2019). Regulation (EU) 2015/2283 of the European Parliament and of the Council. Retrieved from efsa.europa.eu ↩
  34. Government of Canada. (2018). Cannabis Act. Retrieved from canada.ca ↩
  35. Shrivastava, A., et al. (2011). Cannabinoids and cannabinoid receptors: The story so far. International Journal of Neuroscience, 121(7), 349–356. ↩
  36. Philpott, H. T., et al. (2017). A systematic review of cannabis and cannabinoids for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 45(5), 657–672. ↩